High DHCR7 Expression Predicts Poor Prognosis for Cervical Cancer

Figure 3

The prognostic value of DHCR7 for cervical cancer. (a) Kaplan-Meier analysis of OS in low- and high-DHCR7 groups. (b–d) OS in clinicopathological subgroups of squamous cell carcinoma, lymph node metastasis, and radiation therapy. (e) The hazard ratio of different clinicopathological features to OS in different clinicopathological subgroups. (f) Kaplan-Meier analysis of PFI in low- and high-DHCR7 groups. (g–i) PFI in clinicopathological subgroups of squamous cell carcinoma, lymph node metastasis, and radiation therapy. (j) The hazard ratio of different clinicopathological features to PFI in different clinicopathological subgroups. (K) Kaplan-Meier analysis of DSS in low- and high-DHCR7 groups. (l–n) DSS in clinicopathological subgroups of squamous cell carcinoma, lymph node metastasis, and radiation therapy. (o) The hazard ratio of different clinicopathological features to DSS in different clinicopathological subgroups. OS: overall survival; DSS: disease-specific survival; PFI: progression-free interval; DFI: disease-free interval.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)